J-Ring M Forte Tablet ER is a combination oral antihyperglycemic medication containing Metformin 1000 mg and Teneligliptin 20 mg, designed for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing insulin sensitivity, and improving peripheral glucose uptake and utilization. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin levels, which inhibit glucagon release, thereby increasing insulin secretion and decreasing blood glucose levels. The extended-release formulation of J-Ring M Forte ensures a sustained therapeutic effect, improving glycemic control with once-daily dosing and potentially enhancing patient compliance. This combination is indicated for adult patients inadequately controlled on diet and exercise alone or on monotherapy with either agent. It is essential to monitor renal function prior to initiation and periodically during therapy, as Metformin is contraindicated in patients with significantly impaired renal function. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often diminish with continued use. J-Ring M Forte should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular blood glucose monitoring, under the supervision of a healthcare professional.